DDInter1543 DDInter1376
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Protriptyline {u} (Compound) resembles {v} (Compound) Maprotiline
Protriptyline {u} (Compound) resembles {v} (Compound) Cyclobenzaprine
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Protriptyline {u} (Compound) binds {v} (Gene) CYP2D6
Protriptyline {u} (Compound) upregulates {v} (Gene) MAP7
Protriptyline {u} (Compound) downregulates {v} (Gene) NUP93
Protriptyline {u} (Compound) causes {v} (Side Effect) Parotid swelling
Protriptyline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Protriptyline {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Protriptyline (Compound) resembles Maprotiline (Compound)
Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Protriptyline (Compound) binds CYP2D6 (Gene)
Protriptyline (Compound) upregulates MAP7 (Gene)
Protriptyline (Compound) downregulates NUP93 (Gene)
Protriptyline (Compound) causes Parotid swelling (Side Effect)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Protriptyline may lead to a major life threatening interaction when taken with Pasireotide